Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs (NASDAQ:ALLO)

Core Insights - Allogene Therapeutics is positioning 2026 as a pivotal year, aiming to achieve significant clinical milestones with a focus on speed and rigor [2] - The company is committed to validating its allogeneic platform, emphasizing its role as a primary solution rather than an alternative [2] Financial Outlook - Allogene has extended its cash runway into 2028, indicating a strong financial position to support ongoing and future projects [2] - The company is prioritizing scalable CAR T programs, which are expected to drive growth and innovation in its therapeutic offerings [2]